“Blocking this inversion would not only be sound fiscal policy, it would also act as a strong deterrent to other companies that are contemplating similar tax scams,” Sanders said in the letter sent from his Senate office.

AD

In addition to lowering its effective tax rate significantly, Pfizer will also gain access to $148 billion in profits it earned overseas and currently can’t bring back to the United States without taking a tax hit. Bringing the cash back would have cost the firm $35 billion, according to Americans for Tax Fairness, a left-leaning advocacy group.

“Large multi-national corporations should not be able to avoid paying U.S. taxes when children in America go hungry,” the senator from Vermont said in the letter. “We must demand that these profitable corporations pay their fair share in taxes.”

AD

The acquisition has sparked outrage and frustration throughout Congress. Sanders’s rival for the Democratic presidential nomination, Hillary Clinton, has proposed a new “exit tax” that would crack down on U.S. companies that move their headquarters overseas. But Congress is not likely to take action this year, and Republicans and Democrats remain split on the best way to reform the corporate tax code.

AD

The Treasury Department has already issued rules twice meant to stem the tide of companies moving their headquarters overseas. And Sanders on Friday urged the agency to act again by dismantling some of the tax strategies firms often employ after an inversion.

“We’ve received the letter and will respond to the Senator in due course, as appropriate,” a Treasury Department spokesman said in a statement.

Pfizer declined to comment. But the company has previously said that the merger makes strategic sense and is not structured to move jobs outside the United States.